Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight, potentially making half the population candidates for its weight-loss drugs Ozempic and Wegovy.
The federal government is reluctant to reimburse the so-called GLP-1 drugs for weight loss, but Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can be up to $460 a month.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。